{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.017","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.","statisticalMethod":"Fisher Exact"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.109","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.","statisticalMethod":"Fisher Exact"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.","statisticalMethod":"Fisher Exact"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Week 12. A priori p-value significance threshold: 1-sided ≤0.10.","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"Week 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"0"}]}],"title":"Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"0"}]}],"title":"Week 8"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"2"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"30"},{"comment":"Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.","groupId":"OG004","value":"NA"}]}],"title":"Week 16"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"26"},{"comment":"Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.","groupId":"OG004","value":"NA"}]}],"title":"Week 20"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"24"},{"comment":"Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.","groupId":"OG004","value":"NA"}]}],"title":"Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"98"}],"units":"Participants"}],"description":"ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. An ACR70 Responder is a participant who had ≥70% improvement from baseline in both 68 tender and 66 swollen joint counts and ≥70% improvement in at least 3 of 5 criteria: Patient's and Physician's Global Assessment of Disease Activity, HAQ-DI (assessment of participant's physical function), pain due to RA, and hsCRP. Participants who discontinue before analysis time points are treated as non-responders. Percentage of participants achieving ACR70 response = (number of ACR70 responders) / (number of participants analyzed) \\* 100.","groups":[{"description":"1 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"1 mg LY3009104"},{"description":"2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"2 mg LY3009104"},{"description":"4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"4 mg LY3009104"},{"description":"8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG003","title":"8 mg LY3009104"},{"description":"Placebo administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG004","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received study drug in Parts A and B. Participants who had missing components of the ACR70 index at analysis time points had these components imputed by LOCF.","reportingStatus":"POSTED","timeFrame":"Baseline through Weeks 2, 4, 8, 12, 16, 20, 24","title":"Percentage of Participants Who Achieved an ACR70 Responder Index Response Baseline Through Week 24","type":"SECONDARY","unitOfMeasure":"percentage of participants"}